




MSK Mets & MIIPs



Anthony Tadros March 15, 2018









Q Enter search string

in 🕨

HOME ABOUT THE II WHAT ARE MIIPs? THE DOCUMENTARY MEDIA ENGAGE DONATE

"People deserve to understand what health care options are available to them so they can make the best choices for themselves and their families. That's why we are dedicated to empowering the public through education about MIIPs."

> —Isabel Newton, MD, PhD Chairperson of the Board, Secretary

WITHOUT A SCALPEL EPISODE 2: THE CANCER SNIPERS

Objectives


- Review imaging features of MSK metastatic disease
- Discuss clinical features and treatment algorithms for MSK metastatic disease
- Review minimally invasive techniques used in MSK palliation

MSK Metastases

- Most common site of metastatic disease
- Morbidity
 - Pain
 - Pathologic fracture
 - Neural compromise
 - Myelosuppresion



68 yo F with rhabdomyosarcoma of the thyroid. Case courtesy of Brady Huang, MD.




59 yo F with breast cancer and foot drop.

AJR 2017; 209:713–721 World J Radiol 2015 August 28; 7(8): 202-211

Routes of spread


- Direct extension (e.g. Pancoast's tumor)
- Lymphatic
 - Draining lymph node involves adjacent bone (e.g. vertebral destruction in pelvic carcinoma)
- Hematogenous
 - Arterial immunity to tumor penetration in absence of infection
 - Venous* most common (Batson's plexus → direction connection to IVC/SVC with no valves)
- Intraspinal (e.g. CSF to spinal canal)




Resnick. Bone and Joint Imaging, 2004 Batson OV. Ann Surg. 1940;112:138.

Pathophysiology of bone metastases

- Rich marrow sinusoidal system \rightarrow large endothelial gaps
- Tumor adhesion molecules bind to bone matrix
- Certain tumors upregulate:
 - Osteoclasts (e.g. TNF, PTHrP)→ lysis
 - Osteoblasts (e.g. EGF, IGF) → sclerosis






World J Radiol 2015 28; 7(8): 202-211 Valdez et al (2012) Hematopathology. Journal of Clinical Oncology, 19, 15 2001

Pathophysiology of bone metastases

<u>Osteolytic</u>

- Lung
- Kidney
- Thyroid
- Most SCCs
- Melanoma
- HCC
- Colon
- Bladder



<u>Mixed</u>

- Lung
- Breast
- Cervical
- Bladder
- Testicular
- Gastrointestinal



70 yo F with breast cancer.

<u>Osteoblastic</u>


- Prostate
- Breast
- Carcinoid



79 yo M with prostate cancer.

Common sites of bone metastases

- Thoracolumbar spine + sacrum = vertebral body > posterior element
 Lumbar (52%), Thoracic (36%), Cervical (12%)
- Pelvis
- Ribs
- Sternum
- Femoral and humeral shafts
- Skull (e.g. myeloma, breast lung)



69 yo F with lung cancer



67 yo F with breast cancer. *Resnick. Bone and Joint Imaging, 2004*

Infrequent sites of bone metastases

- Mandible (e.g. myeloma)
- Patella
- Appendicular
 - Hands and Feet \rightarrow lung cancer
- Sites of disease (e.g. Paget's) or surgery (e.g. implant)



98 yo man with biopsy-proven metastasis to calcaneus. History prostate cancer.

Resnick. Bone and Joint Imaging, 2004 World J Radiol 2015 August 28; 7(8): 202-211

Imaging Pearls: Sclerotic lesion

Bone Island

- Spiculated
- Growth < 50% in 1 year
- Normal surrounding marrow
- Can be warm or hot on bone scan



<u>Metastasis</u>

- Less homogenous
- Rim of edema halo sign (99% specific)
- Mean attenuation < 885 HU




69 yo F with breast cancer.

AJR:208, May 2017 AJR 2016; 207:362–368

Planar Bone scan should not be used to exclude or mandate biopsy of a sclerotic lesion. Useful to find additional lesions.

Imaging Pearls: Lytic lesion

- Asymptomatic + nonaggressive sclerotic margin + no treated malignancy = no additional imaging
- Indeterminate \rightarrow MRI
 - Look for Fat (99.5% benign)




AJR:208, May 2017

93 yo F with fall.

Imaging Pearls: Focal marrow abnormality

- Adult red marrow = Axial skeleton, proximal long bone metaphyses
 T1 signal > muscle or disk
- Focal red marrow can appear masslike without macroscopic fat
- In and out of phase → microscopic fat decrease in signal on OOP images when compared to muscle
- If no macro or micro fat \rightarrow 6% malignant
 - Breast, lung, lymphoma, myeloma
 - FDG PET/CT 95% sensitive for mets/lymphoma



86 yo F with right chest wall sarcoma.


AJR:208, May 2017

Soft-tissue metastases

- 1.3% of soft-tissue masses
- Large, painful, deep to fascia
- ~ 50% first presentation of malignancy
 - Lung, skin, kidney



48 yo F with pulmonary artery sarcoma.



33 yo M with biopsy proven rectal cancer metastatic to gluteal musculature.


J Bone Joint Surg Br. 2009 Aug;91(8):1083-5.

Clinical features of bone metastases

- Complication from bone met = skeletal-related event
- A patient with bone met \rightarrow skeletal-related event every 3-6 mos
 - Cluster around periods of progression and reduced treatment options

Clinical features of bone metastases


- Pain
- Pathologic fractures
- Neural compression
- Myelosuppresion
- Deconditioning
- Weakness
- Respiratory compromise
- Hypercalcemia



Clin Cancer Res 2006;12(20 Suppl) 2006 Semin Intervent Radiol 2017;34:121–131. J Gastrointest Oncol 2014;5(6):E113-E116.

Pain

- Most common cause of of cancer-related pain
- Not adequately treated in 56-82% of patients
- Mechanisms
 - Tumor-induced osteolysis
 - Cytokine release
 - Infiltration of nerves
- Nociceptive type \rightarrow damage to tissues
- Neuropathic type \rightarrow damage to nerves




34 yo M with metastatic liposarcoma.

Clin Cancer Res 2006;12(20 Suppl) 2006 Diagnostic and Interventional Imaging (2017) 98 , 627—634 Semin Intervent Radiol 2017;34:328–336

Pain

- Base of skull cranial nerve palsies, neuralgias, headaches
- Vertebral neck and back pain with or without neurologic complication (epidural extension)
- Pelvic and femoral pain in back and lower limbs, mechanical instability



60 yo M with RCC and lung cancer.

Clin Cancer Res 2006;12(20 Suppl) 2006

Pain in the spine

- Periosteum \rightarrow high density of sensory nerve endings
 - Tumor invasion \rightarrow local inflammatory environment
- Medullary \rightarrow little sensory innervation
- Extend directly into exiting nerve roots
- Compress dura or spinal cord
- Pathologic fracture
 - Stabilize when possible

Pathologic fractures

- Reduced load bearing capability \rightarrow microfracture (pain) \rightarrow fracture
 - Most common = ribs and vertebrae
- Most disability = Long bone fracture or epidural extension



37 yo F with metastatic pheochromocytoma.

Clin Cancer Res 2006;12(20 Suppl) 2006

Spinal metastases

- Goals of treatment
 - Palliative pain control
 - Structural stabilization
 - Tumor control
- Patient evaluation
 - Structural integrity
 - Pain
 - Clinical factors



Spinal metastases – Structural assessment

Early surgical evaluation

- Aggressive multilevel or multicolumn disease
- Significant deformity
- Spinal canal encroachment
- Bowel/bladder dysfunction
- Lower extremity weakness or sensory deficits
- Identify pathologic fractures and high risk lesions for future fracture
 - MRI preferred
 - CT Critical cortical boundaries, minimally displaced fractures
 - SPECT/CT myeloma fractures

Spinal metastases – Predicting fracture risk

- Limited data-driven recommendations
- Most validated scoring system → Spinal Instability Neoplastic Score (SINS)
 - Published by Spine Oncology Study Group (2010)
 - Based on literature review and expert opinion somewhat validated

Scores 6 variables

- Location
- Mechanical pain
- Type of bony lesion
- Radiographic alignment
- Vertebral body destruction
- Involvement of posterolateral spinal elements

SPINE Volume 35, Number 22, pp E1221–E1229 Global Spine Journal 2017, Vol. 7(8) 744-748

Element of SINS	Score
Location	
Junctional (occiput-C2, C7–T2, T11–L1, L5–S1)	3
Mobile spine (C3–C6, L2–L4)	2
Semi-rigid (T3–T10)	1
Rigid (S2–S5)	0
Pain relief with recumbency and/or pain with	
movement/loading of the spine	
Yes	3
No (occasional pain but not mechanical)	1
Pain free lesion	0
Bone lesion	
Lytic	2
Mixed (lytic/blastic)	1
Blastic	0
Radiographic spinal alignment	
Subluxation/translation present	4
De novo deformity (kyphosis/scoliosis)	2
Normal alignment	0
Vertebral body collapse	_
>50% collapse	3
<50% collapse	2
No collapse with >50% body involved	1
None of the above	0
Posterolateral involvement of the spinal elements	
(facet, pedicle or CV joint fracture	
or replacement with tumor)	
Bilateral	3
Unilateral	1
None of the above	ò

	Score (Total = $0-18$)			
	1-6	7-12	13-18	
Clinical categories Binary scale		Potentially unstable Unstable Current or potentially unstable = possil surgical intervention		


SPINE Volume 35, Number 22, pp E1221–E1229 Global Spine Journal 2017, Vol. 7(8) 744-748

Spinal Instability Neoplastic Score (SINS)

Α

69 yo M with RCC presenting with occasional back pain, not changed with posture, and right T10 radicular pain

Semirigid spine (T10) = 1 Lack of mechanical pain = 1 Lytic lesion = 2 Normal alignment = 0 No VB collapse, >50 % involved = 1 Unilateral spinal elements = 1



SPINE Volume 35, Number 22, pp E1221–E1229

Radiation and fracture risk

- Increased pathologic fractures postradiation
 - Conformable external beam radiation therapy (cEBRT)
 - Stereotactic beam radiation therapy (SBRT) or stereotactic radiosurgery (SRS) \rightarrow 15 to 40%
- Occurs several weeks postradiation
 - Highly lytic
 - Elevated SINS


Radiation and fracture risk

• ? Prophylactic stabilization prior to RT

- No level 1 evidence
- Some will perform vertebral augmentation of painful and nonpainful high-risk lesions prior to RT
- Other possible reasons for prophylactic augmentation
 - At levels for screw fixation prior to decompression = prevent screw pullout
 - Adjacent cranial levels to prevent proximal junction failure

Pain assessment

- Baseline pain
 - Visual Analog Scale (VAS), Numeric Rating Scale (NRS) or Brief Pain Inventory (BPI)
- Functional Assessment and mobility
 - Roland Morris Disability Questionnaire (RMDQ) or Oswestry Disability Index (ODI)
- Current pain medication regimen
 - Morphine equivalent daily dose (MEDD)



Semin Intervent Radiol 2017;34:121–131.

Developing a plan of care

- Patient often poorly tolerate prolonged conservative management (e.g. bed rest, bracing, oral analgesics)
 - Benefit from stabilization of fractures (acute/subacute and even > 1 yr unhealed)
- Important considerations
 - Patient age
 - Functional status
 - Tumor type
 - Long-term prognosis
 - Rate of disease progression

Developing a plan of care

- Ideally within multidisciplinary setting
- NOMS decision framework MSKCC
 - Neurologic symptoms
 - Oncologic parameters
 - Mechanical instability
 - Systemic disease/medical comorbidities
- Based on literature review



Semin Intervent Radiol 2017;34:121–131.


Developing a plan of care \rightarrow NOMS decision framework

Neurologic	Oncologic	Mechanical	Systemic	Decision
Low-grade ESCC + no myelopathy	Radiosensitive	Stable		cEBRT
	Radiosensitive	Unstable		Stabilization followed by cEBRT
	Radioresistant	Stable		SRS
	Radioresistant	Unstable		Stabilization followed by SRS
High-grade ESCC \pm myelopathy	Radiosensitive	Stable		cEBRT
	Radiosensitive	Unstable		Stabilization followed by cEBRT
	Radioresistant	Stable	Able to tolerate surgery	Decompression/stabilization followed by SRS
	Radioresistant	Stable	Unable to tolerate surgery	cEBRT
	Radioresistant	Unstable	Able to tolerate surgery	Decompression/stabilization followed by SRS
	Radioresistant	Unstable	Unable to tolerate surgery	Stabilization followed by cEBRT

Stabilization = percutaneous cement augmentation, percutaneous pedicle screw instrumentation, and open instrumentation

Oncologist. 2013 Jun; 18(6): 744–751.

Developing a plan of care \rightarrow NOMS decision framework



Oncologist. 2013 Jun; 18(6): 744–751.

Radiation


- Mainstay treatment of spinal metastases
- Effective pain palliation in some patients
 - 70-80% some pain relief
 - 30% complete pain relief
- Takes several weeks for pain relief
- Pain often recurs \rightarrow 57% of patients at median of 15 wks postradiation

Radiation

• Historically = cEBRT for radiosensitive spinal metastases

- Lymphoma, myeloma, prostate, breast
- Median duration of improvement \rightarrow 11 months
- Radioresistant duration of improvement \rightarrow 3 months
- SBRT/SRS → higher doses to tumors safely
 - Nearly all tumors are radiosensitive
 - High response rates
 - Minimal neurologic side effects
- Increased postradiation fractures with SBRT/SRS
 - Up to 40% vs. < 5% cEBRT
 - ? prophylactic vertebral body augmentation

Developing a plan of care \rightarrow NOMS decision framework




Oncologist. 2013 Jun; 18(6): 744–751.

Surgical decompression

- Long-term ambulatory benefit
- Recommended for young and/or highly function with reasonable long-term prognosis
- Multiple scoring systems to stratify survival after spine surgery for metastatic disease

Developing a plan of care \rightarrow NOMS decision framework



Oncologist. 2013 Jun; 18(6): 744–751.

Vertebral Augmentation

- First described by Harrington in 1981 for pathologic spine fracture
- General features
 - Posterior approach through or adjacent to pedicles
 - +/- cavity creation
 - +/- placement of implant
 - Injection of polymethylmethacrylate (PMMA)


Vertebral Augmentation

- Vertebroplasty = PMMA injection into vertebral body
- Kyphoplasty = Balloon cavity creation + PMMA injection
- Vertebral augmentation = all encompassing
 - Cavity creation or device implantation
 - PMMA Injection

Vertebral Augmentation

- For patients not requiring or appropriate for surgical decompression and/or fixation
- Strong evidence \rightarrow
 - Significant spinal stabilization
 - Functional improvement in osteoporotic and pathologic fractures
 - Pain relief
- Advantages \rightarrow
 - Minimal disruption to chemotherapy and radiation
 - Avoidance of general anesthesia

Developing a plan of care \rightarrow NOMS decision framework



Oncologist. 2013 Jun; 18(6): 744–751.

Spine Ablation

- Complete curative therapy
 - 67% at 1 year → small lesions without significant cortical destruction or posterior element involvement
 - Difficult due to adjacent neurologic structures and predicting ablation zone
- Noncurative cytoreduction
- Pain relief
 - Target bone/tumor interfaces → maximal nerve ending irritation due to local tumor-induced inflammation

Spine Ablation

- Cavity for PMMA may minimize complications
- PMMA for all lytic or partially lytic lesions



Semin Intervent Radiol 2017;34:121–131.

Ablation options

- Chemical
 - Alcohol
- Thermal
 - RFA
 - Microwave
 - Cyroablation
 - MRgUS
 - Laser




AJR:207, September 2016

Chemical ablation \rightarrow Alcohol

- Cell dehydration
- Tumor vessel thrombosis
- Unpredictable extent and volume of tumor ablation
- Preferred for vertebral hemangiomas
 - Subthreshold temperature due to cooling effect of flowing blood
- Test injection \rightarrow estimate tumor perfusion

Thermal ablation

- Induce cell death using extreme change in temperature
- Landmark paper \rightarrow RFA of osteoid osteoma (Rosenthal et al, 1992)
- Choice of ablation method (RFA, MW, cryo, laser)
 - Operator experience
 - Equipment availability
 - Tumor size and location



J Vasc Interv Radiol 2010; 21:S179–S186 AJR:207, September 2016 *Radiology* 1992; 183:29–33

Thermal ablation

- Ablation zone margins \rightarrow need to encompass entire tumor
- Number and position probes \rightarrow ablation zone
- Beware of adjacent critical structures (> 1 cm = safe distance)
 - Skin
 - Nerves (neurotoxic: > 45 °C or < 10°C)
- If unsafe distance \rightarrow protective measures
 - Temperature monitoring = thermal couples
 - Nerve function monitoring = EEG, EMG
 - Thermal insulation (5% dextrose, CO₂, warm saline/ice packs, heat/cold sink)

Thermal ablation

 General anesthesia or moderate to deep sedation with analgesic support


- Needle into osteoid osteoma nidus \rightarrow prostaglandin surge
- Antibiotic prophylaxis



AJR:207, September 2016

Radiofrequency ablation


- RFA = heat delivered by high-energy frequency electric current
- Current flows through patient to grounding pads
 - Grounding pads should be on large bulk soft tissue (e.g. thighs)
 - As far as possible from active electrode
- Bipolar RF probe
 - Active and return electrodes in same probe




J Vasc Interv Radiol 2010; 21:S179–S186

Radiofrequency ablation

- Advantages
 - Long term experience
 - Mature product lines
 - One design includes articulating probe
- Disadvantages
 - Heat-sink effect and tissue charring \rightarrow prevent adequate ablation
 - Highly vascular metastases may benefit from preablation embolization to reduce heat-sink
 - No real-time visualization of ablation zone



J Vasc Interv Radiol 2010; 21:S179–S186



Radiofrequency ablation


- Bone natural barrier for thermal energy
 - Heat does not dissipate through adjacent bone → protects adjacent structures
 - Reactive adjacent bone \rightarrow added insulation
 - "Oven effect"
- Ideal for small soft-tissue lesion surrounded by bone (e.g. osteoid osteoma)
- Subchondral lesion \rightarrow PMMA

Semin Intervent Radiol 2017;34:121–131.

AJR:207, September 2016

Microwave ablation

- Electromagnetic waves in microwave energy spectrum to produce heat
 - Water oscillates trying to align with EM field = heat




J Vasc Interv Radiol. 2010 August ; 21(8 Suppl): S192–S203. AJR:207, September 2016

Microwave ablation

- Advantages
 - Faster
 - Multiple simultaneous probes = larger ablation zone
 - Less sensitivity to bone impedance \rightarrow useful for sclerotic lesions
 - Less heat sink and charring
- Disdvantages
 - High learning curve \rightarrow choice of antennas, frequencies, power output
 - Fragile probes \rightarrow probe fracture or malfunction
 - Sclerotic lesion needs advanced drill access
 - Less predictable ablation zone
 - Heat transmission less efficient in cancellous bone and more reflected at cortex

Semin Intervent Radiol 2017;34:121–131. AJR:207, September 2016




Microwave ablation

- Useful for sclerotic bone lesions (more effective heating)
 - Ceramic tip design may fracture \rightarrow advanced drill access
- Avoiding overheating
 - Temperature monitoring
 - Short ablation cycles

Cryoablation


- Extremely cold temperature \rightarrow cell death
 - Conversion of intra and extracellular water to ice
 - Central necrosis and peripheral apoptosis
- Unlike heat based ablation
 - No charring \rightarrow extracellular matrix maintained
 - Not limited by cortical bone



J Vasc Interv Radiol 2010; 21:S187–S191

Cryoablation

- Probes use compressed argon (cool) and helium (thaw) gas
 - Joule-Thompson effect
 - 2.4 mm probe \rightarrow 3 cm lethal ablation zone
- Important to get very low temperature at a fast rate
 - Double freeze technique 10 min with intervening 5 minute passive thaw
 - Active thaw at end of procedure extract from ice ball
- Lethal and nonlethal temperatures
 - Nonlethal at outer margins
 - Ablation zone planning based on lethal temperatures (-20 °C to -40 °C)



http://www.versandafne.it/en/core-business/cryoablation-prosense/breast-diseases.html

Cryoablation

- Widely used in many organ systems
- Large bulky tumor \rightarrow ablation size and sculpting
- Advantages
 - Depict ablation margins on CT = low density ball
 - Direct analgesic effect
 - Neurologic monitoring = no electrical interference
- Disadvantages
 - Longer ablation time
 - Partial melting needed prior to PMMA
 - Expensive equipment

Semin Intervent Radiol 2017;34:121–131.

AJR:207, September 2016



Conf Proc IEEE Eng Med Biol Soc. 2012 Aug;2012:2327-30.


Laser ablation

- Infrared light energy through optical fiber \rightarrow heat
 - Nd:YAG diode laser fibers
- Small ablation zones up 1.6 cm
- Predictable size of necrosis
- Ideal for osteoid osteoma when RFA contraindicated (e.g. pacemaker)
- MRI-compatible


MR-guided focused ultrasound

- Focused ultrasound delivered within lesion
- Real-time thermal monitoring by MR guidance
- Non-invasive
- Improved physical functioning and symptomatic quality of life measures

Clinical Oncology 30 (2018) 233e242 *Proceedings from the 14th International Symposium on Therapeutic Ultrasound* AIP Conf. Proc. 1821, 140001-1–140001-5;



https://www.philips.com.au/healthcare/education-resources/publications/hotspot/mr-hifu



https://www.philips.com.au/healthcare/education-resources/publications/hotspot/mr-hifu

Pre-ablation planning

- Degree of tumor lysis
- Posterior cortical destruction
- Retropulsion
- Pedicle involvement/fracture → parapedicular access
- Dural invasion
- Neural compression
- Tumor vascularity
- Paraspinous soft-tissue component
- Bone quality

Pre-ablation planning


- Lytic lesions \rightarrow most amenable to treatment
 - Easy access and PMMA injection
- Sclerotic and mixed lesions \rightarrow more challenging
 - Drills for access
- Bipedicular access \rightarrow complete targeting of lesion

A word about myeloma


- Large lytic lesions \rightarrow high incidence of pathologic fractures
 - Upregulation of osteoclasts and plasma cell invasion
- Highly radiosensitive
- Vertebroplasty is an effective treatment
 - PMMA polymerizes in vivo \rightarrow transient temperature elevation
 - Soft tumor \rightarrow some local tumor control
 - Pain control = structural stability and possibly PMMA exothermic process
- Posterior cortical destruction \rightarrow vertebral augmentation implant
 - PEEK coil (e.g. KIVA) or metallic stent
- Ablation not usually necessary




64 yo F with breast cancer. RFA with temperature monitoring, KIVA, and pedicle-plasty. Patient had no pain after procedure. – Case courtesy of Sean Tutton, MD



56 yo with RCC. MWA, temperature monitoring, and KIVA at T9, T11-L1. – Case courtesy of Sean Tutton, MD




68 M with myeloma. KIVA with improved pain and mobility. – Case courtesy of William Lea, MD




Metastatic prostate cancer. RFA with KIVA. – Case courtesy of Blake Parsons, MD



86 yo F with RCC. MWA and KIVA with RT to follow. Patient went home same day without pain. – Case courtesy of William Lea, MD




6 month follow-up with progressive disease and new myelopathy despite RT. Repeat MWA prior to surgery. – Case courtesy of William Lea, MD





46 yo M with lung cancer and pathologic L4 fracture. Articulating RFA with epidural hydrodissection.



52 yo F with lung cancer. Surgical decompression and fusion optimal but complicated by poor bone quality.

- C2 PMMA using transoral approach.
- C5 and C7 PMMA using anterolateral US guided approach.

Semin Intervent Radiol 2017;34:121–131.


Pelvis metastases \rightarrow MIIPS

- Similar work-up as spine lesions \rightarrow assess for instability
- High risk for pathologic fracture (acetabulum, sacroiliac region)
 - Focal or permeative lytic lesion
 - Large size
 - Pain with stress
 - Location
- Minimally displaced fractures
- Cementoplasty, +/- ablation, +/- screw fixation
- Minimal interruption to chemo/RT

Enneking classification

<u>Zone 2</u> = articular part of major long bones (humerus, femur, & tibia)


Greatest risk for mechanical failure



<u>Zones 1 and 3</u> = non-weight-bearing bones of the extremity and trunk (clavicle, sternum, & fibula)

Do not compromise mechanical stability of the pelvis

Metastatic acetabular classification



J Am Acad Orthop Surg 2013;21: 685-695

Acetabular metastases

Nonoperative (disphosphonates, RT)

• Does not compromise posterior column, dome, or medial wall

Surgical reconstruction

- Large acetabular lesion that compromises stability
- Pathologic fracture
- Radioresistant tumor
- Debilitating pain despite nonoperative/interventional management

• Preoperative embolization

- Reduce intraoperative blood loss
- RCC, thyroid, HCC
- Large extraosseous soft tissue mass

Acetabular metastases \rightarrow MIIPs

- Alternative to surgical reconstruction → extensive surgery, potentially significant blood loss, large fluid shifts, SIRS
- Percutaneous cementoplasty
 - Complete pain relief in 15 of 20 patients, x 7.3 months (Scaramuzzo et al)
 - Usually combined with ablation
 - Avoid lateral femoral cutaneous nerve, sciatic nerve, & superior gluteal artery
 - Contraindications = impending/complete fractures, medial wall insufficiency


• Ablation

 Marked decrease in pain scores, analgesic use in 30 patients treated with RFA (Thanos et al)









53 yo M with RCC presenting with hip pain. Ablation and fixation. - Case courtesy of William Lea, MD







69 yo M with RCC. Embolization, RFA, and PMMA with neuromonitoring – Case courtesy of Kris Schramm, MD







53 yo with myeloma. Fixation with cementoplasty. – Case courtesy of William Lea, MD







67 yo with RCC. Embolization, ablation, and fixation with cementoplasty. Walked out of hospital next day. – Case courtesy of Kris Schramm, MD



61 yo F with thyroid cancer and painful fracture s/p I-131 and RT. Walking same day. – Case courtesy of William Lea, MD

Proximal femur metastases

- Most reliable predictor of impending fracture \rightarrow mechanical pain
 - Cannot withstand physical stress = risk for fracture
- Mirel scoring system \rightarrow prophylactic fixation score 9+
 - High mortality and morbidity in cancer patients
- Cementoplasty +/- screw fixation
 - Cementoplasty alone high risk of fracture with cortical involvement > 30 mm or prior lesser trochanter fracture

R.J. Pignolo et al. (eds.), *Fractures in the Elderly*, Aging Medicine J Vasc Interv Radiol 2012; 23:1311–1316

Mirels' scoring system for predicting risk of pathological fracture. Prophylactic fixation is recommended with a score of 9 or above¹⁰

Score	1	2	3		
Site	Upper limb	Lower limb	Pertrochanteric		
Pain	Mild	Moderate	Functional		
Lesion	Blastic	Mixed	Lytic		
Sizea	<1/3	1/3	>2/3		


^a As seen on plain radiograph, maximum destruction of cortex in any view.

Fracture risk and recommendation from Mirels' scoring system¹⁰


Score Fracture risk Recommendation

8

Prophylactic fixation is recommended 33%-100% ≥9 Clinical judgment should be used 15% Observation and radiation therapy ≤ 7 <4% can be used



61 yo M with metastatic RCC. MWA, screw fixation cementoplasty. Home same day. – Case courtesy of Sean Tutton, MD




History of metastatic cholangiocarcinoma to bilateral femurs. Intraoperative MWA to reduce hemorrhage prior to IMNs. – Case courtesy of William Lea, MD




HCC metastasis with pain. MWA and cementoplasty. – Case courtesy of Sean Tutton, MD






49 yo M with myeloma with pain s/p RT.
Scapular screw fixation.
– Case courtesy of William Lea, MD



History of RCC in lunate. RFA and cementoplasty. Great pain relief – now able to use screw driver again. – Case courtesy of William Lea, MD




78 yo M with pancreatic cancer and chronic opioid use for 8/10 constant chest wall pain from T2/3 rib metastases.

RFA of T2-4 intercostal nerves. 0/10 pain postop.

– Case courtesy of Kris Schramm, MD

MSK MIIP Complications


- Overall, infrequent
- Hemorrhage and infection are most common
- latrogenic fracture
- Burns (e.g. grounding pad site)
- Non-target ablation
 - Neurovascular structures = central and peripheral nerves
 - Cartilage damage = juxtaepiphyseal location




53 yo F with metastatic sarcoma to right sacral ala treated with cementoplasty.

Extravasation of cement into S1 neuroforamen.







62 yo F with lymphoma and right paraspinal mass. T9 intercostal artery pseudoaneurysm post biopsy.





Semin Intervent Radiol 2015;32:163–173

Outcomes

- Pain palliation (multiple prospective multicenter clinical trials)
 - 4-6 point decrease in mean pain score in 3-6 mos follow-up
 - Reduction in analgesic dose
 - No head to head RCT between ablation and RT
 - One matched cohort study \rightarrow RT + RFA > RT alone
- Local control of oligometastatic disease
 - Five or fewer metastases
 - Studies in patients with limited renal, breast, and prostate cancer
 - Highly variable local tumor control rates = 36 97%
 - Can postpone or avoid initiation of systemic therapy

Outcomes

TABLE I: Outcomes of Percutaneous Ablation of Skeletal Metastases for Pain Palliation

Study	Ablation Device	No. of Patients (No. of Tumors)	Mean Tumor Size (cm)	Mean Pain Score Changeª	No. (%) of Patients With Reduced Pain	Follow-Up (mo)	No. (%) of Major Complications
Goetz et al. [48]	RFA	43 (43)	6.3	7.9–1.4 (6.5/10)	41 (95)	6	3 (7)
Dupuy et al. [49]	RFA	55 (55)	5.2	NR (14.2/100)	NR	3	3 (5)
Wallace et al. [50] ^b	RFA	72 (110)	NR	8.0-2.9 (5.1/10)	45 (78)	1	4 (6)
Callstrom et al. [51]	CA	61 (69)	4.8	7.1–1.4 (5.7/10)	42 (69)	6	1 (2)
Prologo et al. [52]	CA	50 (54)	NR	8-3 (5/10)	47 (94)	3	4 (8)
Tomasian et al. [53] ^b	CA	14 (31)	NR	8-3 (5/10)	14 (100)	10	2 (14)
Pusceddu et al. [11]	MWA	18 (21)	5.3	5.6-0.5 (5.1/10)	17 (94)	3	0
Kastler et al. [10]	MWA	15 (25)	4.7	7.2-1.8 (5.4/10)	14 (93)	6	1 (7)

Outcomes

TABLE 2: Outcomes of Percutaneous Ablation for Local Tumor Control of Bone and Soft-Tissue Metastases


Study	Tumor Histology	Site	Ablation Modality	Mean Size (cm)	No. of Patients (No. of Tumors)	Local Control No. (%)	Survival Rate	Follow-Up (mo)	No. (%) of Major Complications ^a
Bang et al. [35]	NSCLC	Other ^b	CA	3.1	8 (18)	17 (94)	NR	11	2 (11)
Bang et al. [36]	Renal	Other ^b	CA	3.7	27 (48)	47 (97)	NR	16	1 (2)
McMenomy et al. [54]	Mixed	MSK	CA	2.0	40 (52)	45 (87)	91% 1 year, 84% 2 years	21	2 (5)
Littrup et al. [55]	Mixed	ST	CA	3.3	126 (251)	225 (90)	NR	11	5 (2)
Deschamps et al. [56]	Mixed	Bone	RFA, CA	NR	89 (122)	67% 1 year	91% 1 year	22.8	11 (9)
Welch et al. [57]	Renal	Other ^b	RFA, CA	NR	NR (46)	43 (93)	NR	22.5	0
Aubry et al. [58]	Mixed	MSK	MWA	5.5	13 (16)	4 (36)	NR	12	0
Wallace et al. [59]	Mixed	Spine	RFA	NR	NR (55)	70% 1 year	NR	7.9	0
Tomasian et al. [53]	Mixed	Spine	CA	NR	14 (31)	30 (97)	NR	10	0
Erie et al. [37]	Prostate	MSK	RFA, CA	1.6	16 (18)	15 (83)	100% 2 years	27	0

AJR:209, October 2017

Abscopal effect

- Ablation and transarterial therapies stimulate local and systemic immune responses
- Responses are mediated by immune checkpoint proteins
- Early studies show synergy between ablation and immune checkpoint inhibition
 - Tumor response remote from treated tumor

JVIR 2017 Vol 28, Issue 11, Pages 1487–1494



© 2016 American Association for Cancer Research

Conclusion

- Musculoskeletal metastatic disease is common and a significant source of pain and disability
- Multidisciplinary care is key in the treatment of these patients
- Several minimally invasive options are available and play an increasingly important role in the palliation and treatment of these patients

Thank you!